Literature DB >> 1905659

Genetic transformation of various species of Enterococcus by electroporation.

A Friesenegger1, S Fiedler, L A Devriese, R Wirth.   

Abstract

A transformation system for Enterococcus faecalis was developed which uses untreated (i.e., non-protoplasted) cells and the electroporation technique. The optimized protocol resulted in transformation efficiencies of up to 4 x 10(6) transformants per microgram of plasmid DNA. All strains of E. faecalis tested could be transformed by this method, albeit with differing transformation efficiencies. Using the protocol optimized for E. faecalis we successfully transformed Enterococcus faecium, E. hirae, E. malodoratus and E. mundtii.

Entities:  

Mesh：

Year:  1991        PMID： 1905659     DOI： 10.1016/0378-1097(91)90106-k

Source DB:  PubMed          Journal:  FEMS Microbiol Lett        ISSN： 0378-1097            Impact factor:   2.742


  20 in total

1.  Restoration of vancomycin susceptibility in Enterococcus faecalis by antiresistance determinant gene transfer.

Authors:  C Torres Viera; S Tsiodras; H S Gold; E P Coakley; C Wennersten; G M Eliopoulos; R C Moellering; R T Inouye
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

2.  Development of a thermally regulated broad-spectrum promoter system for use in pathogenic gram-positive species.

Authors:  David A Schofield; Caroline Westwater; Brian D Hoel; Phillip A Werner; James S Norris; Michael G Schmidt
Journal:  Appl Environ Microbiol       Date:  2003-06       Impact factor: 4.792

3.  Differences in the Enterococcus faecalis lsa locus that influence susceptibility to quinupristin-dalfopristin and clindamycin.

Authors:  Kavindra V Singh; Barbara E Murray
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

4.  Transcriptional regulation of the citrate gene cluster of Enterococcus faecalis Involves the GntR family transcriptional activator CitO.

Authors:  Víctor S Blancato; Guillermo D Repizo; Cristian A Suárez; Christian Magni
Journal:  J Bacteriol       Date:  2008-09-19       Impact factor: 3.490

5.  Characterization of dihydrofolate reductase genes from trimethoprim-susceptible and trimethoprim-resistant strains of Enterococcus faecalis.

Authors:  T M Coque; K V Singh; G M Weinstock; B E Murray
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

6.  Fine-tuned transcriptional regulation of malate operons in Enterococcus faecalis.

Authors:  Pablo Mortera; Martín Espariz; Cristian Suárez; Guillermo Repizo; Josef Deutscher; Sergio Alarcón; Víctor Blancato; Christian Magni
Journal:  Appl Environ Microbiol       Date:  2012-01-13       Impact factor: 4.792

7.  Enterococcus faecalis bearing aggregation substance is resistant to killing by human neutrophils despite phagocytosis and neutrophil activation.

Authors:  R M Rakita; N N Vanek; K Jacques-Palaz; M Mee; M M Mariscalco; G M Dunny; M Snuggs; W B Van Winkle; S I Simon
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

8.  Chromosomally and Extrachromosomally Mediated High-Level Gentamicin Resistance in Streptococcus agalactiae.

Authors:  Parham Sendi; Martina Furitsch; Stefanie Mauerer; Carlos Florindo; Barbara C Kahl; Sarah Shabayek; Reinhard Berner; Barbara Spellerberg
Journal:  Antimicrob Agents Chemother       Date:  2016-01-04       Impact factor: 5.191

9.  Enterococcus faecalis utilizes maltose by connecting two incompatible metabolic routes via a novel maltose 6'-phosphate phosphatase (MapP).

Authors:  Abdelhamid Mokhtari; Víctor S Blancato; Guillermo D Repizo; Céline Henry; Andreas Pikis; Alexa Bourand; María de Fátima Álvarez; Stefan Immel; Aicha Mechakra-Maza; Axel Hartke; John Thompson; Christian Magni; Josef Deutscher
Journal:  Mol Microbiol       Date:  2013-03-14       Impact factor: 3.501

10.  Cytotoxicity of hydrogen peroxide produced by Enterococcus faecium.

Authors:  Terence I Moy; Eleftherios Mylonakis; Stephen B Calderwood; Frederick M Ausubel
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.